[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [White cells and leukaemia](https://durgical.com/en/haematology/areas/white-cells/) › Toxicities of blood-cancer treatment by drug class

# Toxicities of blood-cancer treatment by drug class

- Treatment and support

Every cancer drug has a side effect that is predictable from how it works. Knowing each class's signature harm lets you prevent it or spot it early.

Updated Nov 15, 2026

## Key points

- [Cyclophosphamide](https://durgical.com/en/pharmacology/cyclophosphamide/) / [ifosfamide](https://durgical.com/en/pharmacology/ifosfamide/) → haemorrhagic cystitis (acrolein) → [mesna](https://durgical.com/en/pharmacology/mesna/).
- Anthracyclines → cumulative cardiomyopathy → echocardiogram.
- [Vincristine](https://durgical.com/en/pharmacology/vincristine/) → neuropathy and [constipation](https://durgical.com/en/conditions/constipation-and-faecal-impaction/); never intrathecal.
- [Bleomycin](https://durgical.com/en/pharmacology/bleomycin/) → lung fibrosis; [cisplatin](https://durgical.com/en/pharmacology/cisplatin/) → kidney, hearing, [low magnesium](https://durgical.com/en/conditions/hypomagnesaemia/).
- [Asparaginase](https://durgical.com/en/pharmacology/asparaginase/) → pancreatitis, clots, [low fibrinogen](https://durgical.com/en/haematology/fibrinogen-disorders-too-little-faulty-or-used-up/).
- [Fludarabine](https://durgical.com/en/pharmacology/fludarabine/) → [Pneumocystis](https://durgical.com/en/microbiology/pneumocystis-jirovecii/), autoimmune haemolysis, irradiated blood.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Common traps
- Elsewhere in DurgiPedia

- Clinical Each class and its signature harm

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

Drugs used for leukaemia, lymphoma and myeloma share some toxicities because they all attack dividing cells (marrow suppression, mucositis, hair loss, nausea, infertility), and each class adds its own signature harm to a particular organ. The harms are early (days to weeks: low counts, mucositis, [tumour lysis](https://durgical.com/en/conditions/tumour-lysis-syndrome/)), late (months: neuropathy, lung fibrosis) or very late (years: [heart failure](https://durgical.com/en/conditions/heart-failure/), second cancers). Regimens and doses are chosen by specialist teams and are not given here.

## How to think about it

Think of every class as a weapon with two kinds of damage. The shared damage falls on every fast-dividing tissue: marrow, gut lining, hair and gonads. The signature damage depends on the weapon's chemistry or where the body clears it, and is predictable: the bladder that collects a toxic breakdown product, the heart muscle that cannot replace itself, the long nerves that rely on microtubules. Learn the signature, and you know what to monitor.

## What to know

- Shared by most cytotoxics: marrow nadir about 7–14 days after a cycle, mucositis, hair loss, nausea and vomiting, infertility, harm to a fetus and a later risk of second cancers.
- [Alkylating agents](https://durgical.com/en/pharmacology/classes/alkylating-agents/) (cyclophosphamide, ifosfamide, [melphalan](https://durgical.com/en/pharmacology/melphalan/), [busulfan](https://durgical.com/en/pharmacology/busulfan/), [bendamustine](https://durgical.com/en/pharmacology/bendamustine/)): haemorrhagic cystitis from acrolein (prevented with mesna and fluids), infertility, and second MDS or AML years later.
- Anthracyclines ([doxorubicin](https://durgical.com/en/pharmacology/doxorubicin/), [daunorubicin](https://durgical.com/en/pharmacology/daunorubicin/)): cardiomyopathy that grows with the cumulative dose, red urine, and severe tissue injury if the drug leaks out of the vein.
- [Antimetabolites](https://durgical.com/en/pharmacology/classes/antimetabolites/): [methotrexate](https://durgical.com/en/pharmacology/methotrexate/) (mucositis, kidney injury, [liver](https://durgical.com/en/anatomy/liver/) damage; [leucovorin](https://durgical.com/en/pharmacology/calcium-folinate/) rescue; held in fluid collections), [cytarabine](https://durgical.com/en/pharmacology/cytarabine/) (high-dose: cerebellar ataxia and [conjunctivitis](https://durgical.com/en/conditions/conjunctivitis/)), fludarabine (deep T-cell suppression, Pneumocystis, autoimmune haemolysis).
- Microtubule drugs (vincristine, [vinblastine](https://durgical.com/en/pharmacology/vinblastine/)) and [proteasome](https://durgical.com/en/biochemistry/enzymes/proteasome/) inhibitors ([bortezomib](https://durgical.com/en/pharmacology/bortezomib/)): [peripheral neuropathy](https://durgical.com/en/conditions/peripheral-neuropathy/); vincristine also causes constipation and ileus and is fatal if given into the spinal fluid.
- Others: cisplatin (kidney, hearing, low [magnesium](https://durgical.com/en/biochemistry/topics/magnesium/)), bleomycin (lung fibrosis), asparaginase (pancreatitis, clots, low fibrinogen, allergy), [thalidomide](https://durgical.com/en/pharmacology/thalidomide/) and [lenalidomide](https://durgical.com/en/pharmacology/lenalidomide/) (venous clots, birth defects), [tretinoin](https://durgical.com/en/pharmacology/tretinoin/) and arsenic (differentiation syndrome; arsenic lengthens the QT).

## How it is done (and why)

- Before treatment: count, kidney and liver tests, heart scan before anthracyclines, hepatitis B and HIV tests, fertility counselling, pregnancy test.
- Prevent the predictable: antiemetics, mesna with ifosfamide or high-dose cyclophosphamide, tumour-lysis and infection prophylaxis.
- Check identity and route twice: vinca alkaloids are given only intravenously, in a minibag, never near intrathecal drugs.
- During treatment: counts before each cycle; teach patients that fever during the nadir is an emergency.
- Track cumulative exposure for drugs with a lifetime limit (anthracyclines, bleomycin) and repeat heart imaging as the protocol requires.
- After treatment: long-term follow-up for heart failure, second cancers, infertility, thyroid and lung problems, often for life after childhood cancer.

## Each class and its signature harm

| Class | Examples | Signature harm | How it is prevented or watched |
| --- | --- | --- | --- |
| Alkylating agents | Cyclophosphamide, ifosfamide, melphalan, busulfan | Haemorrhagic cystitis, infertility, second MDS/AML after 5–10 years | Mesna and fluids, [fertility preservation](https://durgical.com/en/obstetrics-gynaecology/fertility-preservation/), long-term counts |
| Anthracyclines and other topoisomerase II drugs | Doxorubicin, daunorubicin, [etoposide](https://durgical.com/en/pharmacology/etoposide/) | Cardiomyopathy (anthracyclines); second AML within a few years | Echocardiogram, cumulative dose limit, [dexrazoxane](https://durgical.com/en/pharmacology/dexrazoxane/) in selected patients |
| Antimetabolites | Methotrexate, cytarabine, fludarabine | Mucositis and kidney injury; cerebellar toxicity; deep immunosuppression | Drug levels and leucovorin rescue; neurological checks; Pneumocystis prophylaxis and irradiated blood |
| Microtubule drugs | Vincristine, vinblastine | Neuropathy, constipation; fatal if intrathecal | Neurological review, [bowel care](https://durgical.com/en/nursing/bowel-elimination-constipation-enemas-and-faecal-impaction/), strict route checks |
| Platinum and bleomycin | Cisplatin, [carboplatin](https://durgical.com/en/pharmacology/carboplatin/), bleomycin | Kidney and hearing damage; lung fibrosis | Hydration and magnesium; hearing tests; lung function, caution with high [oxygen](https://durgical.com/en/pharmacology/oxygen/) |
| Asparaginase | Asparaginase | Pancreatitis, clots, low fibrinogen, allergy, high [glucose](https://durgical.com/en/biochemistry/molecules/glucose/) | Amylase or lipase, fibrinogen and glucose; watch for clots |

## Risks and precautions

- [Breathlessness](https://durgical.com/en/physiology/hypercapnia-and-dyspnea-what-excess-co-does-and-why-breathlessness-is-felt/) in a lymphoma survivor treated with an anthracycline years earlier may be heart failure; ask about past chemotherapy.
- Blood in the urine during cyclophosphamide or ifosfamide treatment suggests haemorrhagic cystitis; in transplant patients a virus (BK) can cause the same picture.
- Patients who received fludarabine, bendamustine or a purine analogue need irradiated blood components to prevent transfusion-associated [graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/).
- [Rituximab](https://durgical.com/en/pharmacology/rituximab/) and other B-cell drugs can reactivate hepatitis B: test before treatment and give antiviral prophylaxis when markers are positive.
- Bleomycin-exposed patients can develop lung injury with high oxygen concentrations during later surgery; tell the anaesthetist.

## Monitoring and next step

- Full count before each cycle and at the expected nadir if symptoms appear.
- [Creatinine](https://durgical.com/en/biochemistry/molecules/creatinine/), electrolytes including magnesium, and liver tests; methotrexate levels after high-dose treatment.
- Echocardiogram or other heart imaging before and during anthracycline treatment.
- Hepatitis B surface antigen and core antibody, and HIV, before immunochemotherapy.
- Fibrinogen, glucose and [pancreatic enzymes](https://durgical.com/en/pharmacology/pancrelipase/) during asparaginase; urine for blood during alkylating agents.

## Common traps

- **Waiting for symptoms to check the heart on anthracyclines**: damage is often silent until it is advanced, so imaging is planned
- **Thinking vincristine is safe because it hardly lowers the counts**: its harm is to nerves and bowel, and intrathecal vincristine is fatal
- **Giving high-flow oxygen freely after bleomycin**: high oxygen can trigger or worsen bleomycin lung injury
- **Giving methotrexate to a patient with ascites or a [pleural effusion](https://durgical.com/en/conditions/pleural-effusion/)**: the drug pools in the fluid and leaks out slowly, prolonging toxicity
- **Blaming every late blood problem on relapse**: a second MDS or AML after alkylating agents or [topoisomerase II](https://durgical.com/en/biochemistry/enzymes/topoisomerases/) drugs is a separate disease

## Test yourself

Think of the answer, then tap the question to see it.

## A woman receiving cyclophosphamide for lymphoma develops painful visible blood in the urine. Which mechanism explains it, and how is it prevented?

Acrolein, a breakdown product concentrated in the urine, injures the bladder lining; hydration and mesna, which binds acrolein, help prevent it.

## A 30-year-old treated for Hodgkin lymphoma at 15 now has breathlessness and leg swelling. Which past drug class should be asked about first, and why?

Anthracyclines: they cause a cumulative, dose-related cardiomyopathy that can appear years after treatment.

## Why is vincristine always given intravenously in a minibag and kept away from intrathecal drugs?

Vincristine injected into the spinal fluid destroys the nervous system and is almost always fatal; separating routes prevents this known error.

## Which drug class explains AML appearing six years after treatment for myeloma, and how is it different from relapse?

Alkylating agents such as melphalan cause therapy-related MDS/AML, often with chromosome 5 or 7 loss; it is a new, usually high-risk disease, not the old cancer returning.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/toxicities-of-blood-cancer-treatment-by-drug-class/)

## Elsewhere in DurgiPedia

- [Side effects of cancer treatment: nausea, mucositis, hair loss, fatigue and appetite](https://durgical.com/en/nursing/side-effects-of-cancer-treatment-nausea-mucositis-hair-loss-fatigue-and-appetite/)
- [Giving chemotherapy safely: hazardous-drug handling, extravasation, spills and waste](https://durgical.com/en/nursing/giving-chemotherapy-safely-hazardous-drug-handling-extravasation-spills-and-wast/)
- [The mouth during cancer treatment: mucositis, dry mouth and osteonecrosis](https://durgical.com/en/dentistry/the-mouth-during-cancer-treatment-mucositis-dry-mouth-and-osteonecrosis/)
- [Drugs acting on nucleotide metabolism](https://durgical.com/en/biochemistry/topics/drugs-acting-on-nucleotide-metabolism/)
- [Myelodysplastic neoplasms](https://durgical.com/en/general-pathology/myelodysplastic-neoplasms/)
- [The child with cancer: neutropenic precautions, mucositis, nausea, the central line and the family](https://durgical.com/en/nursing/the-child-with-cancer-neutropenic-precautions-mucositis-nausea-the-central-line/)

## Connections

## Related 8

- [How leukaemia is treated: induction, consolidation, targeted drugs and support](https://durgical.com/en/haematology/how-leukaemia-is-treated-induction-consolidation-targeted-drugs-and-support/)
- [Fever with low neutrophils: the first hour](https://durgical.com/en/haematology/fever-with-low-neutrophils-the-first-hour/)
- [Tumour lysis syndrome: prevent, recognise, treat](https://durgical.com/en/haematology/tumour-lysis-syndrome-prevent-recognise-treat/)
- [Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)](https://durgical.com/en/haematology/antibodies-bispecifics-and-car-t-cells-how-they-work-and-their-emergencies/)
- [Supportive care in blood cancers](https://durgical.com/en/haematology/supportive-care-in-blood-cancers/)
- [Growth factors and marrow stimulants: G-CSF, ESAs, TPO receptor agonists](https://durgical.com/en/haematology/growth-factors-and-marrow-stimulants-g-csf-esas-tpo-receptor-agonists/)
- [Stem cell transplantation: autologous or allogeneic, and what can go wrong](https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/)
- [Staging and treating lymphoma: PET-CT, the Lugano stages and treatment principles](https://durgical.com/en/haematology/staging-and-treating-lymphoma-pet-ct-the-lugano-stages-and-treatment-principles/)

## Related conditions 7

- [Febrile neutropenia](https://durgical.com/en/conditions/febrile-neutropenia/)
- [Tumour lysis syndrome](https://durgical.com/en/conditions/tumour-lysis-syndrome/)
- [Dilated cardiomyopathy](https://durgical.com/en/conditions/dilated-cardiomyopathy/)
- [Peripheral neuropathy (diabetic and other)](https://durgical.com/en/conditions/peripheral-neuropathy/)
- [Myelodysplastic syndromes](https://durgical.com/en/conditions/myelodysplastic-syndromes/)
- [Acute leukaemia (AML and ALL)](https://durgical.com/en/conditions/acute-leukaemia/)
- [Pneumocystis pneumonia (PCP)](https://durgical.com/en/conditions/pneumocystis-pneumonia/)

## In Pharmacology 14

- [Cyclophosphamide](https://durgical.com/en/pharmacology/cyclophosphamide/)
- [Ifosfamide](https://durgical.com/en/pharmacology/ifosfamide/)
- [Mesna](https://durgical.com/en/pharmacology/mesna/)
- [Doxorubicin](https://durgical.com/en/pharmacology/doxorubicin/)
- [Daunorubicin](https://durgical.com/en/pharmacology/daunorubicin/)
- [Dexrazoxane](https://durgical.com/en/pharmacology/dexrazoxane/)
- [Methotrexate](https://durgical.com/en/pharmacology/methotrexate/)
- [Cytarabine](https://durgical.com/en/pharmacology/cytarabine/)
- [Fludarabine](https://durgical.com/en/pharmacology/fludarabine/)
- [Vincristine](https://durgical.com/en/pharmacology/vincristine/)
- [Cisplatin](https://durgical.com/en/pharmacology/cisplatin/)
- [Bleomycin](https://durgical.com/en/pharmacology/bleomycin/)

## See all 14

- [Asparaginase](https://durgical.com/en/pharmacology/asparaginase/)
- [Bortezomib](https://durgical.com/en/pharmacology/bortezomib/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Chemotherapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/chemotherapy) (National Cancer Institute (NCI), 2026); [Side Effects of Cancer Treatment](https://www.cancer.gov/about-cancer/treatment/side-effects) (National Cancer Institute (NCI), 2026); [Anthracycline Toxicity](https://www.ncbi.nlm.nih.gov/books/NBK599501/) (StatPearls (NCBI Bookshelf), 2024); [Methotrexate](https://www.ncbi.nlm.nih.gov/books/NBK556114/) (StatPearls Publishing (NCBI Bookshelf), 2024).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/toxicities-of-blood-cancer-treatment-by-drug-class/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/toxicities-of-blood-cancer-treatment-by-drug-class/
